EpiBiologics Raises $107M in Series B Funding

EpiBiologics is preparing a first human trial of its lead antibody, designed to remove tumour-associated EGFR while limiting effects on healthy tissue.

Round size
$107M
Stage
Series B
Headquarters
United States
Announced
Jan 8, 2026

Targeted protein removal

The EpiTAC platform builds bispecific antibodies that selectively degrade extracellular membrane and soluble proteins. It is developing candidates for cancer and immune-system diseases.

Lead programme

EPI-326 is designed to target cancer-driving forms of EGFR. At the announcement, the company planned an early-2026 first-in-human trial in lung cancer and head-and-neck cancer.

Where the funding goes

  • Advance multiple pipeline programmes, including EPI-326 into clinical trials.

Sources

  1. EpiBiologics: funding announcement
  2. Crunchbase News: January 3–9 US funding roundup
03 / Related rounds

Related funding rounds

01
Series C+ · Biotech

Parabilis Medicines

Cell-penetrating peptide medicines targeting proteins involved in cancer.

Led by RA Capital Management, Fidelity, Janus Henderson Investors
$305M
02
Series C+ · Biotech

Cellares

Cellares manufactures cell therapies for biopharmaceutical companies using automated production and quality-control systems designed to replace labor-intensive contract manufacturing.

Led by BlackRock, Eclipse
$257M
03
Seed · Neurotechnology

Merge Labs

Merge Labs researches brain-computer interfaces that combine molecular engineering, ultrasound and AI to communicate with neural activity without implants inside brain tissue.

$252M